About COP9 signalosome complex subunit 2
COP9 signalosome complex subunit 2 (COPS2) is a protein
from Homo sapiens identified by UniProt accession
P61201, 443 residues long.
MolForge cross-references it against 0 known binders and
48 disease associations.
Target properties
| Protein name | COP9 signalosome complex subunit 2 |
| UniProt accession | P61201 |
| Gene | COPS2 |
| Organism | Homo sapiens |
| Length | 443 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (48)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.45
- lung adenocarcinoma · score 0.21
- low grade glioma · score 0.18
- breast adenocarcinoma · score 0.18
- mean platelet volume · score 0.12
- low density lipoprotein cholesterol measurement · score 0.09
- cortical thickness · score 0.08
- cancer · score 0.08
- thyroid stimulating hormone measurement · score 0.07
- hormone measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P61201-F1 | alphafold | PREDICTED | 85.13 | — |
Amino-acid sequence (443 residues)
MSDMEDDFMC DDEEDYDLEY SEDSNSEPNV DLENQYYNSK ALKEDDPKAA LSSFQKVLEL EGEKGEWGFK ALKQMIKINF KLTNFPEMMN RYKQLLTYIR SAVTRNYSEK SINSILDYIS TSKQMDLLQE FYETTLEALK DAKNDRLWFK TNTKLGKLYL EREEYGKLQK ILRQLHQSCQ TDDGEDDLKK GTQLLEIYAL EIQMYTAQKN NKKLKALYEQ SLHIKSAIPH PLIMGVIREC GGKMHLREGE FEKAHTDFFE AFKNYDESGS PRRTTCLKYL VLANMLMKSG INPFDSQEAK PYKNDPEILA MTNLVSAYQN NDITEFEKIL KTNHSNIMDD PFIREHIEEL LRNIRTQVLI KLIKPYTRIH IPFISKELNI DVADVESLLV QCILDNTIHG RIDQVNQLLE LDHQKRGGAR YTALDKWTNQ LNSLNQAVVS KLA
Explore COP9 signalosome complex subunit 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets